Real-World data reveals how israeli patients use palbociclib for advanced breast cancer
NCT ID NCT04671615
First seen Jan 11, 2026 · Last updated May 05, 2026 · Updated 21 times
Summary
This study tracked 559 adults in Israel with metastatic breast cancer who were prescribed palbociclib (a targeted therapy) as part of their treatment. Researchers wanted to see how the drug was actually used in real life, including which other medicines were combined with it, how long patients stayed on treatment, and what happened next. The goal was to gather information, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Pharmaceuticals Israel Ltd.
Herzliya Pituah, 4672509, Israel
Conditions
Explore the condition pages connected to this study.